Diabetes 51:1493-1498, 2002
© 2002 by the American Diabetes Association, Inc.
Insulin and Rosiglitazone Regulation of Lipolysis and Lipogenesis in Human Adipose Tissue In Vitro
Philip G. McTernan1,
Alison L. Harte1,
Leah A. Anderson1,
Allan Green2,
Stephen A. Smith3,
Julie C. Holder3,
Anthony H. Barnett1,
Margaret C. Eggo1, and
Sudhesh Kumar1
1 Division of Medical Sciences, Department of Medicine, University of Birmingham and Heartlands Hospital, Edgbaston, Birmingham, U.K.
2 Bassett Research Institute, Cooperstown, NY
3 Glaxo-SmithKline, Harlow, U.K.
Lipolysis is an important process determining fuel metabolism, and insulin regulates this process in adipose tissue. The aim of this study was to investigate the long-term effects of insulin, an insulin enhancer (rosiglitazone [RSG]), and insulin in combination with RSG on the regulation of lipolysis and lipogenesis in human abdominal subcutaneous fat. Lipolysis and lipogenesis were assessed by protein expression studies of hormone-sensitive lipase (HSL) (84 kDa) and lipoprotein lipase (LPL) (56 kDa), respectively. In addition, lipolytic rate was assessed by glycerol release assay and tumor necrosis factor (TNF)- release measured by enzyme-linked immunosorbent assay (n = 12). In subcutaneous adipocytes, increasing insulin doses stimulated LPL expression, with maximal stimulation at 100 nmol/l insulin (control, 1.0 ± 0.0 [mean ± SE, protein expression relative to control]; 1 nmol/l insulin, 0.87 ± 0.13; 100 nmol/l insulin, 1.68 ± 0.19; P < 0.001). In contrast, insulin at the 100 nmol/l dose reduced the expression of HSL (100 nmol/l insulin, 0.49 ± 0.05; P < 0.05), while no significant reduction was observed at other doses. Higher doses of insulin stimulated both HSL (1,000 nmol/l insulin, 1.4 ± 0.07; P < 0.01) and LPL (control 1.00 ± 0.0; 1,000 nmol/l insulin, 2.66 ± 0.27; P < 0.01) protein expression. Cotreatment with RSG induced an increased dose response to insulin for LPL and HSL (P < 0.05); RSG alone also increased LPL and HSL expression (P < 0.05). Insulin stimulated TNF- secretion in a dose-dependent manner (P < 0.01); the addition of RSG (10-8 mol/l) reduced TNF- secretion (P < 0.05). In summary, chronic treatment of human adipocytes with insulin stimulates lipolysis and LPL protein expression. The addition of RSG reduced the lipolytic rate and TNF- secretion. The increase in lipolysis is not explained by changes in HSL expression. These data, therefore, may explain in part why hyperinsulinemia coexists with increased circulating nonesterified free fatty acids and increased adiposity in obese and/or type 2 diabetic patients.

CiteULike Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
G. Liu, M. Grifman, J. Macdonald, P. Moller, F. Wong-Staal, and Q.-X. Li
Isoginkgetin enhances adiponectin secretion from differentiated adiposarcoma cells via a novel pathway involving AMP-activated protein kinase
J. Endocrinol.,
September 1, 2007;
194(3):
569 - 578.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Purushotham, A. A. Wendel, L.-F. Liu, and M. A. Belury
Maintenance of adiponectin attenuates insulin resistance induced by dietary conjugated linoleic acid in mice
J. Lipid Res.,
February 1, 2007;
48(2):
444 - 452.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Ranganathan, R. Unal, I. Pokrovskaya, A. Yao-Borengasser, B. Phanavanh, B. Lecka-Czernik, N. Rasouli, and P. A. Kern
The lipogenic enzymes DGAT1, FAS, and LPL in adipose tissue: effects of obesity, insulin resistance, and TZD treatment
J. Lipid Res.,
November 1, 2006;
47(11):
2444 - 2450.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Guldiken, B. Turgut, M. Demir, E. Arikan, M. Kara, O. Vural, A. Tugrul, and J. Fareed
The Effects of Rosiglitazone Treatment on the Fibrinolytic System in Patients with Type 2 Diabetes Mellitus
Clinical and Applied Thrombosis/Hemostasis,
January 1, 2006;
12(1):
55 - 60.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Sutinen, K. Kannisto, E. Korsheninnikova, R. M. Fisher, E. Ehrenborg, T. Nyman, A. Virkamaki, T. Funahashi, Y. Matsuzawa, H. Vidal, et al.
Effects of rosiglitazone on gene expression in subcutaneous adipose tissue in highly active antiretroviral therapy-associated lipodystrophy
Am J Physiol Endocrinol Metab,
June 1, 2004;
286(6):
E941 - E949.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Faraj, A. D. Sniderman, and K. Cianflone
ASP enhances in situ lipoprotein lipase activity by increasing fatty acid trapping in adipocytes
J. Lipid Res.,
April 1, 2004;
45(4):
657 - 666.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Green, J. M. Rumberger, C. A. Stuart, and M. S. Ruhoff
Stimulation of Lipolysis by Tumor Necrosis Factor-{alpha} in 3T3-L1 Adipocytes Is Glucose Dependent: Implications for Long-Term Regulation of Lipolysis
Diabetes,
January 1, 2004;
53(1):
74 - 81.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. G. McTernan, F. M. Fisher, G. Valsamakis, R. Chetty, A. Harte, C. L. McTernan, P. M. S. Clark, S. A. Smith, A. H. Barnett, and S. Kumar
Resistin and Type 2 Diabetes: Regulation of Resistin Expression by Insulin and Rosiglitazone and the Effects of Recombinant Resistin on Lipid and Glucose Metabolism in Human Differentiated Adipocytes
J. Clin. Endocrinol. Metab.,
December 1, 2003;
88(12):
6098 - 6106.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Matsuki, R. Horai, K. Sudo, and Y. Iwakura
IL-1 Plays an Important Role in Lipid Metabolism by Regulating Insulin Levels under Physiological Conditions
J. Exp. Med.,
September 15, 2003;
198(6):
877 - 888.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. A. Virtanen, K. Hallsten, R. Parkkola, T. Janatuinen, F. Lonnqvist, T. Viljanen, T. Ronnemaa, J. Knuuti, R. Huupponen, P. Lonnroth, et al.
Differential Effects of Rosiglitazone and Metformin on Adipose Tissue Distribution and Glucose Uptake in Type 2 Diabetic Subjects
Diabetes,
February 1, 2003;
52(2):
283 - 290.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. G. Patel, J. C. Holder, S. A. Smith, S. Kumar, and M. C. Eggo
Differential Regulation of Lipogenesis and Leptin Production by Independent Signaling Pathways and Rosiglitazone During Human Adipocyte Differentiation
Diabetes,
January 1, 2003;
52(1):
43 - 50.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Motoshima, X. Wu, M. K. Sinha, V. E. Hardy, E. L. Rosato, D. J. Barbot, F. E. Rosato, and B. J. Goldstein
Differential Regulation of Adiponectin Secretion from Cultured Human Omental and Subcutaneous Adipocytes: Effects of Insulin and Rosiglitazone
J. Clin. Endocrinol. Metab.,
December 1, 2002;
87(12):
5662 - 5667.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Diabetes Association.
|
|
| |
|